23:33:55 EDT Mon 19 Oct 2020
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Shell Summary for May 28, 2020

2020-05-28 20:14 ET - Market Summary

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

by Stockwatch Business Reporter

The TSX Venture Exchange gained 3.52 points to close at 544.62 Thursday. Alfredo De Lucrezia's third capital pool shell, Vincero Capital Corp. (VCO: halted), has arranged a pharmaceutical deal for its qualifying transaction. It is acquiring worldwide rights (excluding China) to a potential cancer treatment from a California cancer drug developer called NewGen Therapeutics Inc. The shell, which has 15 million shares issued, will issue 30 million shares to NewGen. In connection with the QT, the shell and NewGen together aim to raise $2.5-million at 20 cents.

NewGen was formed in 2011. That year, it acquired worldwide rights (excluding China) to three potential cancer treatments, including the one that Vincero Capital is now acquiring. NewGen acquired the rights to those three potential drugs from a Chinese firm, Jiangsu Kanion Pharmaceutical Co. Ltd., which trades on the Shanghai Stock Exchange and last closed at the equivalent of $2.54. With 592.88 million shares issued, Jiangsu Kanion's market cap is $1.5-billion.

The remainder is available to Stockwatch subscribers.
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

© 2020 Canjex Publishing Ltd. All rights reserved.


Reader Comments - Comments are open to paying subscribers of Stockwatch and unmoderated, although libelous remarks, obscene language and impersonations may be deleted. Opinions expressed do not necessarily reflect the views of Stockwatch.
For information regarding Canadian libel law, please view the University of Ottawa's FAQ regarding Defamation and SLAPPs.